(Total Views: 361)
Posted On: 09/16/2019 12:18:06 PM
Post# of 150024
I agree CYDY is significantly undervalued and thank you for explaining this valuation model to those who don't understand or crunch numbers often.
One note is the royalty out to Progenics and AbbVie is now reduced to 'up to 10.5%' from the previous 12.5%. This changed in the quarterly filings last year sometime and can be found in the middle of page 7 on the most recent 10-K filing. 2% seems minor, but in your example below of 30K patients, this increases the share price from $3.15 to $3.67 (16.5% increase) given your same assumptions.
One note is the royalty out to Progenics and AbbVie is now reduced to 'up to 10.5%' from the previous 12.5%. This changed in the quarterly filings last year sometime and can be found in the middle of page 7 on the most recent 10-K filing. 2% seems minor, but in your example below of 30K patients, this increases the share price from $3.15 to $3.67 (16.5% increase) given your same assumptions.
(1)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
Scroll down for more posts ▼
